WESTCORT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for WESTCORT (WESTCORT).
Topical corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive actions. Binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine production.
| Metabolism | Topical corticosteroids are metabolized primarily in the liver via cytochrome P450 enzymes, then excreted renally. |
| Excretion | Primarily renal (70-90% as metabolites, <5% unchanged); minor biliary/fecal (10-20%) |
| Half-life | Terminal elimination half-life is 2-4 hours. Clinical context: Requires multiple daily applications for sustained effect; systemic accumulation unlikely with topical use. |
| Protein binding | Approximately 90-95% bound, primarily to corticosteroid-binding globulin (CBG) and albumin. |
| Volume of Distribution | Volume of distribution is approximately 0.3-0.5 L/kg after systemic absorption. Clinical meaning: Indicates distribution primarily into extracellular water; low Vd suggests limited tissue penetration and low systemic exposure with topical use. |
| Bioavailability | Topical: Bioavailability is approximately 1-5% of applied dose through intact skin, higher (up to 30%) with damaged skin or occlusion. Not applicable for other routes. |
| Onset of Action | Topical: Onset of anti-inflammatory effect within 1-2 hours after application. Not applicable for other routes as it is a topical corticosteroid. |
| Duration of Action | Duration of action is 4-8 hours after a single topical application. Clinical notes: Twice or three-times daily application recommended for full effect; may be applied with occlusion for enhanced penetration. |
Apply a thin film to affected area twice daily. Use for no longer than 2 consecutive weeks.
| Dosage form | CREAM |
| Renal impairment | No adjustment required for topical use; systemic absorption is minimal. |
| Liver impairment | No adjustment required for topical use; systemic absorption is minimal. |
| Pediatric use | Use lowest potency preparation; apply sparingly once or twice daily for shortest duration. Avoid use in diaper area or under occlusive dressings. |
| Geriatric use | Use with caution due to increased skin fragility; apply sparingly once or twice daily for shortest duration. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for WESTCORT (WESTCORT).
| Breastfeeding | Topically applied hydrocortisone valerate is minimally absorbed systemically; however, absorption is higher when applied to large areas, damaged skin, or under occlusion. It is unknown whether hydrocortisone valerate is excreted in human milk. The M/P ratio has not been established. Caution is advised; avoid application to the breast area and use the lowest effective dose for the shortest duration. |
| Teratogenic Risk | Topical corticosteroids, including hydrocortisone valerate, are not expected to cause major congenital malformations when used at recommended doses during pregnancy. However, prolonged or excessive use in the first trimester may be associated with a small increased risk of orofacial clefts. In the second and third trimesters, high-potency or prolonged use may increase the risk of fetal growth restriction and adrenal suppression in the neonate. Available data are limited for hydrocortisone valerate specifically. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to any component of the formulation. Untreated bacterial, fungal, viral, or parasitic infections at application site.
| Precautions | Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression. Use on large body surface areas, occlusive dressings, or in pediatric patients increases risk. Local adverse reactions include skin atrophy, striae, telangiectasias, and allergic contact dermatitis. Prolonged use may result in cataracts or glaucoma with periorbital application. |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure and blood glucose in cases of prolonged or high-dose use due to potential adrenal suppression. For extensive use, consider monitoring fetal growth via ultrasound. Neonatal assessment for signs of adrenal insufficiency (e.g., hypoglycemia, poor feeding) if maternal use is prolonged or high-dose near term. |
| Fertility Effects | No specific studies on hydrocortisone valerate effects on fertility are available. Systemic corticosteroids have been associated with menstrual irregularities and reduced sperm count in animal studies, but topical corticosteroids are unlikely to have significant effects given minimal systemic absorption at recommended doses. |